Amyloid-PET imaging offers small improvements in predictions of future cognitive trajectories

被引:8
作者
Ackley, Sarah F. [1 ]
Hayes-Larson, Eleanor [2 ]
Brenowitz, Willa D. [1 ]
Swinnerton, Kaitlin [1 ]
Mungas, Dan [3 ]
Fletcher, Evan [3 ]
Singh, Baljeet [3 ]
Whitmer, Rachel A. [4 ,5 ]
DeCarli, Charles [3 ]
Glymour, M. Maria [1 ]
机构
[1] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA
[2] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA 90024 USA
[3] Univ Calif Davis, Ctr Neurosci, Dept Neurol, Davis, CA 95616 USA
[4] Kaiser Permanente Div Res, Oakland, CA USA
[5] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA USA
关键词
Alzheimer's disease; amyloid-PET; Prediction; Cognitive change; Longitudinal studies; POSITRON-EMISSION-TOMOGRAPHY; DATA SET UDS; ALZHEIMERS-DISEASE; DECLINE; BRAIN; ASSOCIATION; IMPAIRMENT; HYPOTHESIS; DIAGNOSIS; MEDICINE;
D O I
10.1016/j.nicl.2021.102713
中图分类号
R445 [影像诊断学];
学科分类号
100207 ;
摘要
Background: Amyloid beta (A beta) is thought to initiate a cascade of pathology culminating in Alzheimer's disease related cognitive decline. A beta accumulation in brain tissues may begin one to two decades prior to clinical diagnosis of Alzheimer's disease. Prior studies have demonstrated that A beta detected in vivo with positron emission tomography with amyloid ligands (amyloid-PET) predicts contemporaneously measured cognition and future cognitive trajectories. Prior studies have not evaluated the added value of A beta measures in predicting future cognition when repeated past cognitive measures are available. We evaluated the extent to which amyloid-PET improves prediction of future cognitive changes over and above predictions based only on sociodemographics and past cognitive measures. Methods: We used data from participants in the University of California Davis Alzheimer's Disease Research cohort who were cognitively normal at baseline, participated in amyloid-PET imaging, and completed at least three cognitive assessments prior to amyloid-PET imaging (N = 132 for memory andN = 135 for executive function). We used sociodemographic and cognitive measures taken prior to amyloid-PET imaging to predict cognitive trajectory after amyloid-PET imaging and assessed whether measures of amyloid burden improved predictions of subsequent cognitive change. Improvements in prediction were characterized as percent reduction in the mean squared error (MSE) in predicted cognition post amyloid-PET and increase in percent variance explained. Results: The base model using only sociodemographics and past cognitive performance explained the majority of variance in both predicted memory measures (55.6%) and executive function measures (74.5%) following amyloid-PET. Adding amyloid positivity to the model reduced the MSE for memory by 0.2%, 95% CI: (0%, 2.6%), p = 0.48 and for executive function by 3.4%, 95% CI: (0.6%, 10.2%), p = 0.002. This corresponded to an increase in the percent variance explained of 0.1%, 95% CI: (0%, 1.2%) for memory and 0.9%, 95% CI: (0.1%, 2.8%) for executive function. Similar results were obtained using a continuous measure of amyloid burden. Conclusion: In this cohort, the addition of amyloid burden slightly improved predictions of executive function compared to models based only on past cognitive assessments and sociodemographics. When repeated cognitive assessments are available, the additional utility of amyloid-PET in predicting future cognitive impairment may be limited.
引用
收藏
页数:8
相关论文
共 45 条
  • [1] Ackley S., 2021, AMYLOID BURDEN PREDI
  • [2] Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for β-amyloid plaques in Alzheimer's disease
    Agdeppa, ED
    Kepe, V
    Liu, J
    Flores-Torres, S
    Satyamurthy, N
    Petric, A
    Cole, GM
    Small, GW
    Huang, SC
    Barrio, JR
    [J]. JOURNAL OF NEUROSCIENCE, 2001, 21 (24) : art. no. - RC189
  • [3] Influence of tau PET, amyloid PET, and hippocampal volume on cognition in Alzheimer disease
    Aschenbrenner, Andrew J.
    Gordon, Brian A.
    Benzinger, Tammie L. S.
    Morris, John C.
    Hassenstab, Jason J.
    [J]. NEUROLOGY, 2018, 91 (09) : E859 - E866
  • [4] Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer's disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database
    Ben Bouallegue, Faycal
    Mariano-Goulart, Denis
    Payoux, Pierre
    [J]. ALZHEIMERS RESEARCH & THERAPY, 2017, 9
  • [5] Implementing the centiloid transformation for 11C-PiB and β-amyloid 18F-PET tracers using CapAIBL
    Bourgeat, Pierrick
    Dore, Vincent
    Fripp, Jurgen
    Ames, David
    Masters, Colin L.
    Salvado, Olivier
    Villemagne, Victor L.
    Rowe, Christopher C.
    [J]. NEUROIMAGE, 2018, 183 : 387 - 393
  • [6] Comparison between amyloid-PET and CSF amyloid-β biomarkers in a clinical cohort with memory deficits
    Bouter, Caroline
    Vogelgsang, Jonathan
    Wiltfang, Jens
    [J]. CLINICA CHIMICA ACTA, 2019, 492 : 62 - 68
  • [7] Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons
    Donohue, Michael C.
    Sperling, Reisa A.
    Petersen, Ronald
    Sun, Chung-Kai
    Weiner, Michael W.
    Aisen, Paul S.
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2017, 317 (22): : 2305 - 2316
  • [8] Florbetapir F 18 amyloid PET and 36-month cognitive decline: a prospective multicenter study
    Doraiswamy, P. M.
    Sperling, R. A.
    Johnson, K.
    Reiman, E. M.
    Wong, T. Z.
    Sabbagh, M. N.
    Sadowsky, C. H.
    Fleisher, A. S.
    Carpenter, A.
    Joshi, A. D.
    Lu, M.
    Grundman, M.
    Mintun, M. A.
    Skovronsky, D. M.
    Pontecorvo, M. J.
    [J]. MOLECULAR PSYCHIATRY, 2014, 19 (09) : 1044 - 1051
  • [9] Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
    Dubois, Bruno
    Feldman, Howard H.
    Jacova, Claudia
    Hampel, Harald
    Molinuevo, Jose Luis
    Blennow, Kaj
    Dekosky, Steven T.
    Gauthier, Serge
    Selkoe, Dennis
    Bateman, Randall
    Cappa, Stefano
    Crutch, Sebastian
    Engelborghs, Sebastiaan
    Frisoni, Giovanni B.
    Fox, Nick C.
    Galasko, Douglas
    Habert, Marie-Odile
    Jicha, Gregory A.
    Nordberg, Agneta
    Pasquier, Florence
    Rabinovici, Gil
    Robert, Philippe
    Rowe, Christopher
    Salloway, Stephen
    Sarazin, Marie
    Epelbaum, Stephane
    de Souza, Leonardo C.
    Vellas, Bruno
    Visser, Pieter J.
    Schneider, Lon
    Stern, Yaakov
    Scheltens, Philip
    Cummings, Jeffrey L.
    [J]. LANCET NEUROLOGY, 2014, 13 (06) : 614 - 629
  • [10] Fitzmaurice Garrett M, 2012, APPL LONGITUDINAL AN, V998